<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03690869</url>
  </required_header>
  <id_info>
    <org_study_id>R2810-ONC-1690</org_study_id>
    <secondary_id>PNOC 013 (CC#160825)</secondary_id>
    <nct_id>NCT03690869</nct_id>
  </id_info>
  <brief_title>REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma</brief_title>
  <official_title>A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacific Pediatric Neuro-Oncology Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1:

        -  To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810
           (cemiplimab) for children with recurrent or refractory solid or Central Nervous System
           (CNS) tumors

        -  To characterize the pharmacokinetics (PK) of REGN2810 given in children with recurrent
           or refractory solid or CNS tumors

      Phase 2 (Efficacy Phase):

        -  To confirm the safety and anticipated RP2D of REGN2810 to be given concomitantly with
           conventionally fractionated or hypofractionated radiation among patients with newly
           diagnosed diffuse intrinsic pontine glioma (DIPG)

        -  To confirm the safety and anticipated RP2D of REGN2810 given concomitantly with
           conventionally fractionated or hypofractionated radiation among patients with newly
           diagnosed high-grade glioma (HGG)

        -  To confirm the safety and anticipated RP2D of REGN2810 given concomitantly with
           re-irradiation in patients with recurrent HGG

        -  To assess PK of REGN2810 in pediatric patients with newly diagnosed DIPG, newly
           diagnosed HGG, or recurrent HGG when given in combination with radiation

        -  To assess anti-tumor activity of REGN2810 in combination with radiation in improving
           overall survival at 12 months (OS12) among patients with newly diagnosed DIPG

        -  To assess anti-tumor activity of REGN2810 in combination with radiation in improving
           progression-free survival at 12 months (PFS12) among patients with newly diagnosed HGG

        -  To assess anti-tumor activity of REGN2810 in combination with radiation in improving
           overall survival at OS12 among patients with recurrent HGG
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Anticipated">January 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of immune-related adverse events (irAEs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events of special interest (AESIs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of serious adverse events (SAEs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy Grade 3 or higher per CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Baseline to 28 days</time_frame>
    <description>Phase 1: given as monotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 4 weeks post radiation therapy</time_frame>
    <description>Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK for REGN2810 estimated Observed terminal half-life (t1/2)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK for REGN2810 Concentration at end of infusion (Ceoi)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK for REGN2810 Area under the curve (AUC2w)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Phase 1: given as monotherapy Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival among newly diagnosed DIPG and recurrent HGG patients</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival among newly diagnosed HGG patients</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Efficacy Phase: given in combination with radiation therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Phase 1: given as monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to REGN2810 given as monotherapy</measure>
    <time_frame>1st follow-up visit, approximately 25 months</time_frame>
    <description>Phase 1: given as monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to REGN2810 given in combination with radiation</measure>
    <time_frame>1st follow-up visit, approximately 25 months</time_frame>
    <description>Efficacy Phase: given in combination with radiation therapy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Relapsed Solid Tumor</condition>
  <condition>Refractory Solid Tumor</condition>
  <condition>Relapsed Central Nervous System Tumor</condition>
  <condition>Refractory Central Nervous System Tumor</condition>
  <condition>Diffuse Intrinsic Pontine Glioma</condition>
  <condition>High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in both the Solid Tumor Cohort and the CNS Cohort will receive REGN2810 monotherapy. Each Cohort will have 2 subgroups by age (0 to &lt;12 years, 12 to &lt;18 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efficacy with Newly Diagnosed DIPG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>≥ 3 to &lt; 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efficacy with Newly Diagnosed HGG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>≥ 3 to &lt; 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efficacy with Recurrent HGG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>≥ 3 to &lt; 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2810 (monotherapy)</intervention_name>
    <description>To be administered intravenously as monotherapy in Phase 1</description>
    <arm_group_label>Phase 1</arm_group_label>
    <other_name>cemiplimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2810 (maintenance)</intervention_name>
    <description>To be administered intravenously in combination with radiation and then used as maintenance therapy</description>
    <arm_group_label>Efficacy with Newly Diagnosed DIPG</arm_group_label>
    <arm_group_label>Efficacy with Newly Diagnosed HGG</arm_group_label>
    <arm_group_label>Efficacy with Recurrent HGG</arm_group_label>
    <other_name>cemiplimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional or hypofractionated</intervention_name>
    <description>Combined with REGN2810 IV administration</description>
    <arm_group_label>Efficacy with Newly Diagnosed DIPG</arm_group_label>
    <arm_group_label>Efficacy with Newly Diagnosed HGG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Re-irradiation</intervention_name>
    <description>Combined with REGN2810 IV administration</description>
    <arm_group_label>Efficacy with Recurrent HGG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age 0 to &lt;18 years of age (Phase 1)

          2. Age ≥3 and ≤25 years of age (Efficacy Phase)

          3. Karnofsky performance status ≥50 (patients &gt;16 years) or Lansky performance status ≥50
             (patients ≤ 16 years)

          4. Life expectancy &gt;8 weeks

          5. Adequate Bone Marrow Function

          6. Adequate Renal Function

          7. Adequate Liver Function

          8. Adequate Neurologic Function

        Key Exclusion Criteria:

          1. Patients with bulky metastatic disease of the CNS causing Uncal herniation or
             symptomatic midline shift, significant, symptomatic mass effect, or uncontrolled
             neurological symptoms such as seizures or altered mental status

          2. Patients with metastatic spine disease and gliomatosis as documented by diffuse
             involvement of &gt;2 lobes

          3. Patients who are receiving any other investigational anticancer agent(s)

          4. Patients on greater than dexamethasone 0.1 mg/kg/day (maximum 4 mg/day) or equivalent
             dose in alternate corticosteroid, or actively undergoing corticosteroid dose
             escalation in the last 7 days

          5. Patients with a history of allogeneic stem cell transplant

          6. Prior treatment with an agent that blocks the PD-1/PD-L1/PD-L2 pathway

        Note: Other protocol-defined Inclusion/Exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles (CHLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaden Daas, MPH</last_name>
      <phone>323-361-3031</phone>
      <email>sdaas@chla.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanipua Yeh-Nayre</last_name>
      <phone>858-576-1700</phone>
      <phone_ext>ext. 222251</phone_ext>
      <email>lyeh@rchsd.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Mueller, MD</last_name>
      <phone>415-476-3831</phone>
      <email>Sabine.Mueller@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Health System (Children's National Medical Center)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Kilburn</last_name>
      <phone>202-476-5000</phone>
      <email>LKilburn@childrensnational.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida- Neurosurgery</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer King</last_name>
      <phone>352-294-8374</phone>
      <email>jennifer.king@neurosurgery.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins - Pediatric Oncology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Seidl</last_name>
      <phone>410-502-8898</phone>
      <email>kseidl4@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ebb, MD</last_name>
      <phone>617-724-2000</phone>
      <email>DEBB@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/ Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Chi, MD</last_name>
      <phone>617-632-4386</phone>
      <email>susan_chi@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Bendel, MD</last_name>
      <phone>612-813-5940</phone>
      <email>anne.bendel@childrensmn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota / Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Marie Walski</last_name>
      <phone>612-625-7908</phone>
      <email>wals0183@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Rubin, MD</last_name>
      <phone>314-454-4457</phone>
      <email>rubin_j@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabatha Doyle</last_name>
      <phone>901-595-2544</phone>
      <email>tabatha.doyle@stjude.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer &amp; Hematology Centers Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy McCarthy</last_name>
      <phone>832-824-4804</phone>
      <email>ksmccart@texaschildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Newly Diagnosed</keyword>
  <keyword>Recurrent</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

